Standout Papers

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised... 2019 2026 2021 2023 256
  1. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (2019)
    Bernard Zinman, Vaishali Bhosekar et al. The Lancet Diabetes & Endocrinology

Immediate Impact

3 from Science/Nature 86 standout
Sub-graph 1 of 22

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Osteoarthritis
2025 Standout
3 intermediate papers

Works of Desirée Thielke being referenced

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
2020
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
2019

Author Peers

Author Last Decade Papers Cites
Desirée Thielke 574 357 32 169 12 654
Aslam Amod 608 273 38 167 28 758
Trine Saugstrup 383 272 25 121 8 584
Wayne H.-H. Sheu 608 235 16 169 13 830
James Thrasher 450 292 21 108 20 598
Tomoyuki Nishida 631 319 23 180 26 682
Jeffrey Unger 711 363 30 161 14 817
Francis Chun Chung Chow 644 291 37 125 16 833
Pierre Sérusclat 701 367 36 90 25 827
Nobuko Maruyama 554 250 67 77 14 601
Maria Kabisch 369 203 87 254 7 716

All Works

Loading papers...

Rankless by CCL
2026